Elobixibat

Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand

Retrieved on: 
Monday, July 19, 2021
Hepatology, Medical specialties, Anatomy, Branches of biology, Eisai, Bile acid, Elobixibat, Bile

TOKYO, July 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand.

Key Points: 
  • TOKYO, July 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand.
  • Goofice inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon.
  • In Asia (Thailand, Indonesia, Philippines, Malaysia, and Singapore), Eisai is responsible for the commercialization and marketing of this product under a contract with EA Pharma.
  • Eisai will continue to make a further contribution to improve QOL for patients with chronic constipation in Thailand and other Asian countries, through maximization of the product value of Goofice.

Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD

Retrieved on: 
Tuesday, March 10, 2020
Stars, Astronomical objects, Stellar astronomy, Hepatitis, Non-alcoholic fatty liver disease, Elobixibat, Cygnus, Forward-looking statement, Albireo

Albireo expects results from a second NASH/NAFLD trial with elobixibat, sponsored by its Japanese partner EA Pharma, late this year or early next year.

Key Points: 
  • Albireo expects results from a second NASH/NAFLD trial with elobixibat, sponsored by its Japanese partner EA Pharma, late this year or early next year.
  • This is the first clinical trial ever conducted in both NASH and NAFLD patients with an IBAT inhibitor, said Ron Cooper, President and Chief Executive Officer of Albireo.
  • As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur.
  • Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law.